GlassScriptPhysician profile
Melissa Zepp
NPI 1780782946
$514.76
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $344 · 2020: $110 · 2021: $61.37.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $181.86 | 2019-2021 | |
| Glaxosmithkline, LLC. | $68.74 | 2019-2020 | |
| Lilly USA, LLC | $54.19 | 2019 | |
| Janssen Pharmaceuticals, INC | $43.99 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $42.19 | 2019-2020 | |
| Amgen INC. | $40.18 | 2019-2020 | |
| Astrazeneca Pharmaceuticals LP | $24.89 | 2019-2020 | |
| Allergan, INC. | $17.94 | 2020 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $13.97 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.97 | 2019 | |
| Ironwood Pharmaceuticals, INC | $12.84 | 2020 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Zepp listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.